Prostaglandin D 2 metabolites as a biomarker of in vivo mast cell activation in systemic mastocytosis and rheumatoid arthritis

Mast cells (MCs) participate in diseases such as systemic mastocytosis (SM) and allergic conditions. Less well understood is the role of MCs in non‐allergic inflammatory disorders like rheumatoid arthritis (RA). Studying definitive roles for MCs in human diseases has been hampered by the lack of a w...

Full description

Saved in:
Bibliographic Details
Published in:Immunity, Inflammation and Disease Inflammation and Disease, 2016-03, Vol.4 (1), p.64-69
Main Authors: Cho, Catherine, Nguyen, Anna, Bryant, Katherine J., O'Neill, Sean G., McNeil, H. Patrick
Format: Article
Language:English
Subjects:
Anaphylaxis
Asthma
Autoimmune diseases
Biomarkers
Inflammation
Metabolites
Patients
Rheumatoid arthritis
Studies
Urine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c183t-ead7a28b9b239096c86c7c86ce0672e886490ccdd57dbb6ceed440223b5a75a53
cites cdi_FETCH-LOGICAL-c183t-ead7a28b9b239096c86c7c86ce0672e886490ccdd57dbb6ceed440223b5a75a53
container_end_page 69
container_issue 1
container_start_page 64
container_title Immunity, Inflammation and Disease
container_volume 4
creator Cho, Catherine
Nguyen, Anna
Bryant, Katherine J.
O'Neill, Sean G.
McNeil, H. Patrick
description Mast cells (MCs) participate in diseases such as systemic mastocytosis (SM) and allergic conditions. Less well understood is the role of MCs in non‐allergic inflammatory disorders like rheumatoid arthritis (RA). Studying definitive roles for MCs in human diseases has been hampered by the lack of a well‐accepted biomarker for monitoring in vivo MC activation. This study aimed to investigate the utility of urinary tetranor PGDM (T‐PGDM) as a biomarker of in vivo MC activation in patients with SM, and apply this biomarker to assess MC involvement in relation to RA disease activity. A prospective, cross‐sectional cohort study was conducted to measure a major urinary metabolite of prostaglandin D2, T‐PGDM. Urine samples were collected from patients with RA (n = 60), SM (n = 17) and healthy normal controls (n = 16) and T‐PGDM excretion was determined by enzyme immunoassay as nanograms per milligram of urinary creatinine (ng/mg Cr). Mean urinary T‐PGDM excretion was significantly higher (p 
doi_str_mv 10.1002/iid3.94
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2290044246</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2290044246</sourcerecordid><originalsourceid>FETCH-LOGICAL-c183t-ead7a28b9b239096c86c7c86ce0672e886490ccdd57dbb6ceed440223b5a75a53</originalsourceid><addsrcrecordid>eNpNkE1LAzEQhoMoWGrxLwQ8eNo6m2Q_cpT6CQU96HmZTVKburupSVroxd9u1noQhplh5uEd5iXkMod5DsBurNV8LsUJmTAoIBMFq07_9edkFsIGAHLgFYd6Qr5fvQsRPzoctB3oHWW0NxFb19loAsUUtLWuR_9pPHUrmqC93TvaY4hUma6jqKLdY7RuGJfhEKLprfoFnDpEF2wSGTT1a7PrMTqrKfq49jbacEHOVtgFM_urU_L-cP-2eMqWL4_Pi9tlpvKax8ygrpDVrWwZlyBLVZeqGpOBsmKmrkshQSmti0q3bRobLQQwxtsCqwILPiVXR92td187E2KzcTs_pJMNYxJACCbKRF0fKZVMCd6smq236fVDk0Mz-tuM_jZS8B-InW9j</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2290044246</pqid></control><display><type>article</type><title>Prostaglandin D 2 metabolites as a biomarker of in vivo mast cell activation in systemic mastocytosis and rheumatoid arthritis</title><source>Open Access: Wiley-Blackwell Open Access Journals</source><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Cho, Catherine ; Nguyen, Anna ; Bryant, Katherine J. ; O'Neill, Sean G. ; McNeil, H. Patrick</creator><creatorcontrib>Cho, Catherine ; Nguyen, Anna ; Bryant, Katherine J. ; O'Neill, Sean G. ; McNeil, H. Patrick</creatorcontrib><description>Mast cells (MCs) participate in diseases such as systemic mastocytosis (SM) and allergic conditions. Less well understood is the role of MCs in non‐allergic inflammatory disorders like rheumatoid arthritis (RA). Studying definitive roles for MCs in human diseases has been hampered by the lack of a well‐accepted biomarker for monitoring in vivo MC activation. This study aimed to investigate the utility of urinary tetranor PGDM (T‐PGDM) as a biomarker of in vivo MC activation in patients with SM, and apply this biomarker to assess MC involvement in relation to RA disease activity. A prospective, cross‐sectional cohort study was conducted to measure a major urinary metabolite of prostaglandin D2, T‐PGDM. Urine samples were collected from patients with RA (n = 60), SM (n = 17) and healthy normal controls (n = 16) and T‐PGDM excretion was determined by enzyme immunoassay as nanograms per milligram of urinary creatinine (ng/mg Cr). Mean urinary T‐PGDM excretion was significantly higher (p &lt; 0.01) in patients with SM compared to controls (37.2 vs. 11.5 ng/mg Cr) with 65% of SM patients showing elevated levels. One third of patients with RA had elevated T‐PGDM excretion, and the mean level in the RA group (20.0 ng/mg Cr) was significantly higher than controls (p &lt; 0.01). Medications inhibiting cyclooxygenase reduced T‐PGDM excretion. Urinary T‐PGDM excretion appears promising as a biomarker of in vivo MC activity and elevated levels in 33% of patients with RA provides evidence of MC activation in this disease.</description><identifier>ISSN: 2050-4527</identifier><identifier>EISSN: 2050-4527</identifier><identifier>DOI: 10.1002/iid3.94</identifier><language>eng</language><publisher>Bognor Regis: John Wiley &amp; Sons, Inc</publisher><subject>Anaphylaxis ; Asthma ; Autoimmune diseases ; Biomarkers ; Inflammation ; Metabolites ; Patients ; Rheumatoid arthritis ; Studies ; Urine</subject><ispartof>Immunity, Inflammation and Disease, 2016-03, Vol.4 (1), p.64-69</ispartof><rights>2016. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c183t-ead7a28b9b239096c86c7c86ce0672e886490ccdd57dbb6ceed440223b5a75a53</citedby><cites>FETCH-LOGICAL-c183t-ead7a28b9b239096c86c7c86ce0672e886490ccdd57dbb6ceed440223b5a75a53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2290044246/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2290044246?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,44590,75126</link.rule.ids></links><search><creatorcontrib>Cho, Catherine</creatorcontrib><creatorcontrib>Nguyen, Anna</creatorcontrib><creatorcontrib>Bryant, Katherine J.</creatorcontrib><creatorcontrib>O'Neill, Sean G.</creatorcontrib><creatorcontrib>McNeil, H. Patrick</creatorcontrib><title>Prostaglandin D 2 metabolites as a biomarker of in vivo mast cell activation in systemic mastocytosis and rheumatoid arthritis</title><title>Immunity, Inflammation and Disease</title><description>Mast cells (MCs) participate in diseases such as systemic mastocytosis (SM) and allergic conditions. Less well understood is the role of MCs in non‐allergic inflammatory disorders like rheumatoid arthritis (RA). Studying definitive roles for MCs in human diseases has been hampered by the lack of a well‐accepted biomarker for monitoring in vivo MC activation. This study aimed to investigate the utility of urinary tetranor PGDM (T‐PGDM) as a biomarker of in vivo MC activation in patients with SM, and apply this biomarker to assess MC involvement in relation to RA disease activity. A prospective, cross‐sectional cohort study was conducted to measure a major urinary metabolite of prostaglandin D2, T‐PGDM. Urine samples were collected from patients with RA (n = 60), SM (n = 17) and healthy normal controls (n = 16) and T‐PGDM excretion was determined by enzyme immunoassay as nanograms per milligram of urinary creatinine (ng/mg Cr). Mean urinary T‐PGDM excretion was significantly higher (p &lt; 0.01) in patients with SM compared to controls (37.2 vs. 11.5 ng/mg Cr) with 65% of SM patients showing elevated levels. One third of patients with RA had elevated T‐PGDM excretion, and the mean level in the RA group (20.0 ng/mg Cr) was significantly higher than controls (p &lt; 0.01). Medications inhibiting cyclooxygenase reduced T‐PGDM excretion. Urinary T‐PGDM excretion appears promising as a biomarker of in vivo MC activity and elevated levels in 33% of patients with RA provides evidence of MC activation in this disease.</description><subject>Anaphylaxis</subject><subject>Asthma</subject><subject>Autoimmune diseases</subject><subject>Biomarkers</subject><subject>Inflammation</subject><subject>Metabolites</subject><subject>Patients</subject><subject>Rheumatoid arthritis</subject><subject>Studies</subject><subject>Urine</subject><issn>2050-4527</issn><issn>2050-4527</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpNkE1LAzEQhoMoWGrxLwQ8eNo6m2Q_cpT6CQU96HmZTVKburupSVroxd9u1noQhplh5uEd5iXkMod5DsBurNV8LsUJmTAoIBMFq07_9edkFsIGAHLgFYd6Qr5fvQsRPzoctB3oHWW0NxFb19loAsUUtLWuR_9pPHUrmqC93TvaY4hUma6jqKLdY7RuGJfhEKLprfoFnDpEF2wSGTT1a7PrMTqrKfq49jbacEHOVtgFM_urU_L-cP-2eMqWL4_Pi9tlpvKax8ygrpDVrWwZlyBLVZeqGpOBsmKmrkshQSmti0q3bRobLQQwxtsCqwILPiVXR92td187E2KzcTs_pJMNYxJACCbKRF0fKZVMCd6smq236fVDk0Mz-tuM_jZS8B-InW9j</recordid><startdate>201603</startdate><enddate>201603</enddate><creator>Cho, Catherine</creator><creator>Nguyen, Anna</creator><creator>Bryant, Katherine J.</creator><creator>O'Neill, Sean G.</creator><creator>McNeil, H. Patrick</creator><general>John Wiley &amp; Sons, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>201603</creationdate><title>Prostaglandin D 2 metabolites as a biomarker of in vivo mast cell activation in systemic mastocytosis and rheumatoid arthritis</title><author>Cho, Catherine ; Nguyen, Anna ; Bryant, Katherine J. ; O'Neill, Sean G. ; McNeil, H. Patrick</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c183t-ead7a28b9b239096c86c7c86ce0672e886490ccdd57dbb6ceed440223b5a75a53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Anaphylaxis</topic><topic>Asthma</topic><topic>Autoimmune diseases</topic><topic>Biomarkers</topic><topic>Inflammation</topic><topic>Metabolites</topic><topic>Patients</topic><topic>Rheumatoid arthritis</topic><topic>Studies</topic><topic>Urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cho, Catherine</creatorcontrib><creatorcontrib>Nguyen, Anna</creatorcontrib><creatorcontrib>Bryant, Katherine J.</creatorcontrib><creatorcontrib>O'Neill, Sean G.</creatorcontrib><creatorcontrib>McNeil, H. Patrick</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Immunity, Inflammation and Disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cho, Catherine</au><au>Nguyen, Anna</au><au>Bryant, Katherine J.</au><au>O'Neill, Sean G.</au><au>McNeil, H. Patrick</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prostaglandin D 2 metabolites as a biomarker of in vivo mast cell activation in systemic mastocytosis and rheumatoid arthritis</atitle><jtitle>Immunity, Inflammation and Disease</jtitle><date>2016-03</date><risdate>2016</risdate><volume>4</volume><issue>1</issue><spage>64</spage><epage>69</epage><pages>64-69</pages><issn>2050-4527</issn><eissn>2050-4527</eissn><abstract>Mast cells (MCs) participate in diseases such as systemic mastocytosis (SM) and allergic conditions. Less well understood is the role of MCs in non‐allergic inflammatory disorders like rheumatoid arthritis (RA). Studying definitive roles for MCs in human diseases has been hampered by the lack of a well‐accepted biomarker for monitoring in vivo MC activation. This study aimed to investigate the utility of urinary tetranor PGDM (T‐PGDM) as a biomarker of in vivo MC activation in patients with SM, and apply this biomarker to assess MC involvement in relation to RA disease activity. A prospective, cross‐sectional cohort study was conducted to measure a major urinary metabolite of prostaglandin D2, T‐PGDM. Urine samples were collected from patients with RA (n = 60), SM (n = 17) and healthy normal controls (n = 16) and T‐PGDM excretion was determined by enzyme immunoassay as nanograms per milligram of urinary creatinine (ng/mg Cr). Mean urinary T‐PGDM excretion was significantly higher (p &lt; 0.01) in patients with SM compared to controls (37.2 vs. 11.5 ng/mg Cr) with 65% of SM patients showing elevated levels. One third of patients with RA had elevated T‐PGDM excretion, and the mean level in the RA group (20.0 ng/mg Cr) was significantly higher than controls (p &lt; 0.01). Medications inhibiting cyclooxygenase reduced T‐PGDM excretion. Urinary T‐PGDM excretion appears promising as a biomarker of in vivo MC activity and elevated levels in 33% of patients with RA provides evidence of MC activation in this disease.</abstract><cop>Bognor Regis</cop><pub>John Wiley &amp; Sons, Inc</pub><doi>10.1002/iid3.94</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2050-4527
ispartof Immunity, Inflammation and Disease, 2016-03, Vol.4 (1), p.64-69
issn 2050-4527
2050-4527
language eng
recordid cdi_proquest_journals_2290044246
source Open Access: Wiley-Blackwell Open Access Journals; Publicly Available Content Database; PubMed Central
subjects Anaphylaxis
Asthma
Autoimmune diseases
Biomarkers
Inflammation
Metabolites
Patients
Rheumatoid arthritis
Studies
Urine
title Prostaglandin D 2 metabolites as a biomarker of in vivo mast cell activation in systemic mastocytosis and rheumatoid arthritis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T18%3A02%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prostaglandin%20D%202%20metabolites%20as%20a%20biomarker%20of%20in%20vivo%20mast%20cell%20activation%20in%20systemic%20mastocytosis%20and%20rheumatoid%20arthritis&rft.jtitle=Immunity,%20Inflammation%20and%20Disease&rft.au=Cho,%20Catherine&rft.date=2016-03&rft.volume=4&rft.issue=1&rft.spage=64&rft.epage=69&rft.pages=64-69&rft.issn=2050-4527&rft.eissn=2050-4527&rft_id=info:doi/10.1002/iid3.94&rft_dat=%3Cproquest_cross%3E2290044246%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c183t-ead7a28b9b239096c86c7c86ce0672e886490ccdd57dbb6ceed440223b5a75a53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2290044246&rft_id=info:pmid/&rfr_iscdi=true